World Health Organization site
Skip Navigation Links

Please fill this short user satisfaction survey


Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 3 April 2023
Main ID:  NCT05094050
Date of registration: 20/10/2021
Prospective Registration: Yes
Primary sponsor: AbbVie
Public title: Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult Participants With Parkinson's Disease
Scientific title: Parkinson's Disease: A Comparative Study of Levodopa and Carbidopa Bioavailability Following Foslevodopa/Foscarbidopa Infusion at Different Subcutaneous Sites in Parkinson's Disease Patients
Date of first enrolment: January 18, 2022
Target sample size: 16
Recruitment status: Completed
URL:  https://clinicaltrials.gov/show/NCT05094050
Study type:  Interventional
Study design:  Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).  
Phase:  Phase 1
Countries of recruitment
United States
Contacts
Name:     ABBVIE INC.
Address: 
Telephone:
Email:
Affiliation:  AbbVie
Key inclusion & exclusion criteria

Inclusion Criteria:

- Diagnosis of idiopathic Parkinson's disease (PD) that is Levodopa-responsive.

- Must be taking a minimum of 400 mg/day of levodopa equivalents (LE) and be judged by
the investigator to have motor symptoms inadequately controlled by current therapy.

- Must have recognizable/identifiable "Off" and "On" states (motor fluctuations), and
have a minimum daily average of 2.5 hours of "Off" time (with a minimum of 2 hours of
"Off" time each day).

Exclusion Criteria:

- History of significant skin conditions or disorders (e.g., psoriasis, atopic dermatitis,
etc.) or evidence of recent sunburn, acne, scar tissue, tattoo, open wound, branding, or
colorations that in the investigator's opinion would interfere with the infusion of the
study drug or could interfere with study assessments.



Age minimum: 30 Years
Age maximum: N/A
Gender: All
Health Condition(s) or Problem(s) studied
Parkinson's Disease
Intervention(s)
Drug: ABBV-951
Primary Outcome(s)
Swing of LD [Time Frame: Up to 8 Days]
Area Under the Plasma Concentration-Time Curve (AUC) for the 24-hour Interval of LD [Time Frame: Up to 8 Days]
Area Under the Plasma Concentration-Time Curve (AUC) for the 24-hour Interval of CD [Time Frame: Up to 8 Days]
Maximum Observed Plasma Concentration (Cmax) of Levodopa (LD) [Time Frame: Up to 8 Days]
Minimum Observed Plasma Concentration (Cmin) of CD [Time Frame: Up to 8 Days]
Degree of Fluctuation (DFL) of CD [Time Frame: Up to 8 Days]
Degree of Fluctuation (DFL) of LD [Time Frame: Up to 8 Days]
Minimum Observed Plasma Concentration (Cmin) of LD [Time Frame: Up to 8 Days]
Swing of CD [Time Frame: Up to 8 Days]
Maximum Observed Plasma Concentration (Cmax) of Carbidopa (CD) [Time Frame: Up to 8 Days]
Secondary Outcome(s)
Secondary ID(s)
M20-339
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history Please fill this short user satisfaction survey